abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb

Esta página não está disponível em Português e está sendo exibida em English

Artigo

28 Jan 2011

Author:
Alex Nussbaum, Bloomberg [USA]

J&J Generics Deal May Speed AIDS Drug Access in Africa, India

...Tibotec Pharmaceuticals [part of Johnson & Johnson]...has agreed to let three generic drugmakers provide copies of [its experimental AIDS drug] in sub-Saharan Africa, India and parts of Asia if it’s approved by regulators...[T]hat could make the pill available for a hundredth of the price that customers pay in the United States, said Mitchell Warren, executive director of the New York-based AIDS Vaccine Advocacy Coalition...The deal may have a downside if it means J&J is rejecting calls for drugmakers to license patents to The Medicines Patent Pool...[James] Love [director of Knowledge Ecology International] said...The agreements “are the first part of a comprehensive access strategy for TMC278,” Karen Manson, a Tibotec spokeswoman, said....